Antonio Passaro: Honored to have presented the SOHO-02 clinical trial

Antonio Passaro shared a post on LinkedIn:

“I am truly honored to have presented the SOHO-02 clinical trial in the Trials in Progress section at ESMO24.

As one of the Principal Investigators of this global, open-label, randomized, multicenter study, I am proud to be leading efforts to evaluate the efficacy and safety of BAY-2927088 in patients with advanced non–small cell lung cancer (NSCLC) harboring HER2 mutations.

In SOHO-02, patients with advanced NSCLC and activating HER2 mutations will be randomly assigned to receive either BAY-2927088 or the current standard of care (cisplatin/carboplatin plus pemetrexed and pembrolizumab).

BAY-2927088 is an oral, reversible tyrosine kinase inhibitor specifically targeting HER2 (ERBB2) mutations. The drug has received Breakthrough Therapy designation from both the US FDA and the Chinese Center for Drug Evaluation for patients with unresectable or metastatic NSCLC who have previously undergone treatment.

Furthermore, the recent updated results from the SOHO-1 trial, presented by Xiuning Le at WCLC24, have been highly encouraging, reinforcing the potential of BAY-2927088 as a promising new therapy for HER2-mutant NSCLC.

I am pleased to announce that the first patients has already been enrolled in Malaysia, and we are excited to initiate the study globally in the coming weeks!

I am incredibly grateful to be part of this groundbreaking research, and I look forward to advancing new treatment options for patients with HER2-mutant NSCLC.”

Source: Antonio Passaro/LinkedIn

More posts featuring Antonio Passaro on oncodaily.com

Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. He focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC).

Dr. Antonio Passaro is an Associate Editor for Lung Cancer Journal by Elsevier and the Chair of the ESMO Press & Media Affairs Committee.

He is also a faculty member for the Lung and Other Thoracic Tumours faculty group and the ESMO-MCBS Extended Working Group. He also holds editorial positions and key roles in societies like ESMO and AIOM.